NFKB1 and breast carcinoma: APRIL binds to the transmembrane activator (TACI) on tumor cell surfaces, activating both the NF-κB and mitogen-activated protein kinase (MAPK) pathways, thereby driving abnormal proliferation of breast cancer cells (49, 50).